Recent

% | $
Quotes you view appear here for quick access.

Seattle Genetics, Inc. Message Board

  • terridiamond158 terridiamond158 Sep 11, 2013 9:06 AM Flag

    LINK Biotechnology News on Catalyst Date. 9/10/13

    Biotechnology News : FDA - SGEN by 9/14/13 POSTED.

    Biotechnology Events
    The FDA is expected to take action on the application by September 14, 2013. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of HL and sALCL, that was granted accelerated approval by the FDA in August 2011 for relapsed HL and relapsed sALCL.
    “Our goal is to broaden the ADCETRIS U.S. labeling claims to provide both patients and physicians the opportunity to incorporate ADCETRIS into additional HL and sALCL treatment settings,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. “The FDA’s acceptance of our sBLA
    submission is an important step towards making ADCETRIS available in the retreatment and extended duration setting, and we look forward to the regulatory outcome.”

 
SGEN
47.87+0.53(+1.12%)Jul 31 4:00 PMEDT